Td Asset Management Inc Cyma Bay Therapeutics, Inc. Transaction History

Td Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$12.63 - $24.47 $828,528 - $1.61 Million	65,600 Added 71.34%	157,556 $3.72 Million
Q3 2023 Oct 27, 2023	BUY	$10.86 - $17.62 $998,642 - $1.62 Million	91,956 New	91,956 $1.37 Million
Q4 2018 Feb 01, 2019	SELL	$6.54 - $11.74 $144,534 - $259,454	-22,100 Closed	0 $0
Q3 2018 Nov 01, 2018	SELL	$10.88 - $14.52 $110,976 - $148,104	-10,200 Reduced 31.58%	22,100 $245,000
Q2 2018 Jul 31, 2018	SELL	$10.66 - $14.38 $47,618 - $64,235	-4,467 Reduced 12.15%	32,300 $433,000

Q1 2018 May 11, 2018	BUY	$9.0 - $15.16 $330,903 - $557,387	36,767 New	36,767 $478,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.